Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...

The results from a sub-population of patients in Lilly's SURMOUNT-1 trial suggest that tirzepatide could provide an alternative that, at least in theory, could require less dramatic lifestyle changes.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

The authors examined the percent change in body weight from randomization to week 72 (SURMOUNT-1, -2, and -3) or week 52 (SURMOUNT-4), as well as the proportions of participants achieving the ...

The findings are congruent with recently reported real-world data that found a 6.9% greater weight loss at 1 year with tirzepatide versus semaglutide. Average weight lost in SURMOUNT-5 was also ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

31.6% of people taking Zepbound achieved at least 25% body weight loss compared to 16.1% of those taking Wegovy. The overall safety profile of Zepbound in SURMOUNT-5 was similar to previously ...

Surmount Logistics, Chennai being a startup company incorporated only in the year 2022, strongly believe that their employees ...